|
|
5TH
ROUND OF INTERNATIONAL INTERLABORATORY CONTROL PROGRAM FOR THERAPEUTIC DRUG
MONITORING IN HIV INFECTION
PrefaceDear
participant, Here
you will find the results of your participation in the 5th round of
the International Interlaboratory Quality Control Program for Therapeutic Drug
Monitoring in HIV Infection. This report summarizes the results you reported
together with our comments to your results. The comments are made by dr. D.
Burger and mrs. J.
Droste. The
samples for this 5th round were prepared by weighing the required
amount of the different drugs and adding them to human plasma. The plasma has
been obtained from HIV-negative healthy volunteers. Sodiumazide (0.1%) was added
as a preservative. Most of the samples were shipped by regular mail (Stability
of samples has been proved by Hugen et al, J Chrom Biomed Appl 1999; 727:
139-149); however about 10 participants preferred to receive their samples on dry-ice. The
objectives of this 5th round were to define sources of error in
bioanalytical methods, to contribute to the optimisation of the bioanalysis of
antiretroviral drugs and to establish interconvertibility of analytical results
among laboratories and methods. Participating laboratories were asked to measure
the concentration of the antiretroviral drugs and to report the results before
the indicated date. We would like to draw your attendance to the article of
Droste et al (JAIDS 2003; 32: 287-291) where this quality control program is
described. Together
with the samples, you received a clinical case with a questionnaire. You were
asked to answer the questions. The clinical case and the answers
are discussed
by dr. D. Burger. Together
with this report, you will find the form you are required to use to report the
analytical values of the samples for the 6th round. Please note the
dead-line of December 17th, 2003. dr.
D.J. Touw, PharmD, PhD. October
2003 |
|
U kunt een e-mailbericht met vragen of opmerkingen over deze website
verzenden aan
info@kkgt.nl.
|